Lytix Biopharma AS is a biotechnology company specializing in the development of novel cancer immunotherapies. The primary function of Lytix Biopharma is to design and advance therapies that harness the body’s immune system to recognize and eradicate cancer cells. Its focus is on enhancing the effectiveness of cancer treatments through the development of oncolytic molecules that stimulate immune responses. Operating primarily in the biotechnology and healthcare sectors, Lytix Biopharma's innovative approach targets unmet medical needs, particularly in the treatment of tumors that may not respond well to conventional therapies. With its cutting-edge research and development processes, Lytix Biopharma plays a crucial role in the pharmaceutical landscape, offering potential new therapies that could improve outcomes for cancer patients globally. By pioneering solutions in immunotherapy, the company contributes to the broader goals of advancing personalized medicine and optimizing therapeutic results in oncology.